BETHESDA, Md.--(BUSINESS WIRE)-- Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that Christian Itin, Ph.D., the Company’s President and CEO, will present a corporate overview at two upcoming investor conferences:
10th Annual Needham Healthcare Conference
Tuesday, April 5, at 2:40 PM ET
New York, NY
Leerink Swann Cancer Roundtable
Thursday, April 7, at 1:55 PM ET
New York, NY
The presentations will be webcast live and may be accessed by visiting the Micromet website at www.micromet.com. A replay of the webcasts will also be available on the Company's website.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.
CONTACT:
Micromet, Inc.
Jennifer Neiman
Director, Corporate Communications
240-235-0246
[email protected]
KEYWORDS: United States North America Maryland New York
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical
MEDIA: